Format

Send to

Choose Destination
J Huntingtons Dis. 2015;4(3):219-229. doi: 10.3233/JHD-150163.

Safety of Striatal Infusion of siRNA in a Transgenic Huntington's Disease Mouse Model.

Author information

1
Department of Medicine, University of Massachusetts Medical School, Worcester, MA.
2
Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA.
3
Department of Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA.
4
Department of Massachusetts General Hospital, Charlestown, MA.
#
Contributed equally

Abstract

BACKGROUND:

The immune system In Huntington's disease (HD) is activated and may overreact to some therapies. RNA interference using siRNA lowers mutant huntingtin (mHTT) protein but could increase immune responses.

OBJECTIVE:

To examine the innate immune response following siRNA infusion into the striatum of wild-type (WT) and HD transgenic (YAC128) mice.

METHODS:

siRNAs (2'-O-methyl phosphorothioated) were infused unilaterally into striatum of four month-old WT and YAC128 mice for 28 days. Microglia number and morphology (resting (normal), activated, dystrophic), cytokine levels, and DARPP32-positive neurons were measured in striatum immediately or 14 days post-infusion. Controls included contralateral untreated striatum, and PBS and sham treated striata.

RESULTS:

The striata of untreated YAC128 mice had significantly fewer resting microglia and more dystrophic microglia than WT mice, but no difference from WT in the proportion of activated microglia or total number of microglia. siRNA infusion increased the total number of microglia in YAC128 mice compared to PBS treated and untreated striata and increased the proportion of activated microglia in WT and YAC128 mice compared to untreated striata and sham treated groups. Cytokine levels were low and siRNA infusion resulted in only modest changes in those levels. siRNA infusion did not change the number of DARPP32-positive neurons.

CONCLUSION:

Findings suggest that siRNA infusion may be a safe method for lowering mHTT levels in the striatum in young animals, since treatment does not produce a robust cytokine response or cause neurotoxicity. The potential long-term effects of a sustained increase in total and activated microglia after siRNA infusion in HD mice need to be explored.

KEYWORDS:

Huntington’s disease; cytokines; immune response; microglia; siRNA

PMID:
26444021
PMCID:
PMC5058343
DOI:
10.3233/JHD-150163
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for IOS Press Icon for PubMed Central
Loading ...
Support Center